General Information and Variability Data of DT
DT ID DTD0002
Gene Name ABCC2
Protein Name Multidrug resistance-associated protein 2
Synonyms ABC30; ABCC2; ATP-binding cassette sub-family C member 2; CMOAT; CMOAT1; CMRP; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; DJS; MRP2
Gene ID
1244
UniProt ID
Q92887
TCDB ID
3.A.1.208.2
DT Family ATP-Binding Cassette (ABC) Superfamily
Drug Conjugate Transporter (DCT) Family (ABCC)
Tissue Specificity Expression in the hepatocytes, renal proximal tubule cells, and intestinal epithelia, and expression in the gallbladder, bronchi, and placenta, It is, however, present in brain capillaries of hippocampus specimens from patients with temporal lobe epilepsy, and in malignant tumor cells from renal clear-cell, hepatocellular, ovarian, colorectal, lung, breast, and gastric carcinomas
Function This transporter mediates hepatobiliary excretion of numerous organic anions and may function as a cellular cisplatin transporter.
Disease(s) Chronic myelogenous leukemia [ICD-11: 2A20.0]
Colorectal cancer [ICD-11: 2B91]
Epilepsy [ICD-11: 8A6Z]
Gout [ICD-11: FA25]
Organ transplant rejection [ICD-11: NE84]
Ovarian cancer [ICD-11: 2C73]
Pemphigus vulgaris [ICD-11: EB40.0]
Maintenance of normal sinus rhythm [ICD-11: BC81.3]
Pneumonia [ICD-11: CA40]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Acetaminophen Drug Info Pain [ICD-11: MG30-MG7Z] Approved [1]
Acyclovir Drug Info Shingles [ICD-11: 1.00E+91] Approved [2]
Adefovir Drug Info Herpes simplex virus infection [ICD-11: 1F00] Approved [3]
Ampicillin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [4]
Arsenic trioxide Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [5]
Azithromycin Drug Info Traveler's diarrhea [ICD-11: ME05.1] Approved [6]
Carbamazepine Drug Info Epilepsy [ICD-11: 8A6Z] Approved [7]
Cefadroxil Drug Info Gram-positive & negative bacteria infections [ICD-11: 1A00-1H0Z] Approved [8]
Cefodizime Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [4]
Ceftriaxone Drug Info Pneumonia [ICD-11: CA40] Approved [4]
Cerivastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [9]
Cholic acid Drug Info Synthesis disorders [ICD-11: 5C52.10] Approved [10]
Cidofovir Drug Info Cytomegalovirus infections [ICD-11: 1D82] Approved [4]
Cisplatin Drug Info Testicular cancer [ICD-11: 2C80] Approved [11]
Cyclosporine Drug Info Xerophthalmia [ICD-11: 5B55.Y] Approved [12]
Dehydroepiandrosterone sulfate Drug Info Dyspareunia [ICD-11: GA12] Approved [13]
Dinoprostone Drug Info Medical abortion [ICD-11: JA00.1] Approved [14]
Docetaxel Drug Info Lung cancer [ICD-11: 2C25] Approved [15]
Doxorubicin Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [16]
Enalapril Drug Info High blood pressure [ICD-11: BA00] Approved [17]
Epirubicin Drug Info Node-positive breast cancer [ICD-11: 2C60-2C6Z] Approved [4]
Erythromycin Drug Info Pelvic inflammatory disease [ICD-11: GA05] Approved [18]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [19]
Etoposide Drug Info Testicular cancer [ICD-11: 2C80] Approved [20]
Ezetimibe Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [21]
Fluorescein Drug Info Ocular disease [ICD-11: 9E1Z] Approved [22]
Fluorouracil Drug Info Stomach cancer [ICD-11: 2B72] Approved [23]
Folic acid Drug Info Vitamin deficiency [ICD-11: 5B55-5B7Z] Approved [24]
Gadobenate dimeglumine Drug Info CNS imaging [ICD-11: XD47Y1] Approved [25]
Gatifloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [26]
Gemifloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [27]
Glutathione Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [28]
Glycyrrhizin Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Approved [29]
Grepafloxacin Drug Info Chronic bronchitis [ICD-11: CA20.1] Approved [30]
Indinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [31]
Irinotecan Drug Info Colorectal cancer [ICD-11: 2B91] Approved [32]
Leucovorin Drug Info Colorectal cancer [ICD-11: 2B91] Approved [33]
Lopinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [34]
Mesalazine Drug Info Recurrent ventricular fibrillation [ICD-11: BC71.1] Approved [35]
Methotrexate Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [36]
Mitoxantrone Drug Info Metastatic breast cancer [ICD-11: 2C6Y] Approved [4]
Mycophenolate mofetil Drug Info Pemphigus vulgaris [ICD-11: EB40.0] Approved [37]
Mycophenolic acid Drug Info Organ transplant rejection [ICD-11: NE84] Approved [38]
Nelfinavir Drug Info Sars coronavirus infections [ICD-11: 1D92] Approved [4]
Nilotinib Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [39]
Octreotide Drug Info Maintenance of normal sinus rhythm [ICD-11: BC81.3] Approved [40]
Olamufloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [29]
Olmesartan medoxomil Drug Info High blood pressure [ICD-11: BA00] Approved [41]
Oxaliplatin Drug Info Colorectal cancer [ICD-11: 2B91] Approved [42]
Paclitaxel Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [43]
Pemetrexed Drug Info Malignant pleural mesothelioma [ICD-11: 2C26.0] Approved [29]
Pemirolast Drug Info Itching of the eye due to allergic conjunctivitis [ICD-11: 9A60.02] Approved [29]
Phenobarbital Drug Info Seizure [ICD-11: 8A68] Approved [44]
Phenytoin Drug Info Seizures following neurosurgery [ICD-11: 8A6Z] Approved [45]
Pitavastatin Drug Info Primary hyperlipidemia and mixed dyslipidemia [ICD-11: 5C8Z] Approved [46]
Pitavastatin calcium Drug Info Dyslipidaemias [ICD-11: 5C8Z] Approved [4]
Pravastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [47]
Probenecid Drug Info Hyperuricaemia [ICD-11: 5C55.Y] Approved [48]
Raltitrexed Drug Info Rectal cancer [ICD-11: 2B92] Approved [49]
Regorafenib Drug Info Metastatic colorectal cancer [ICD-11: 2B91] Approved [50]
Rifampicin Drug Info Tuberculosis [ICD-11: 1B1Z] Approved [51]
Ritonavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [31]
Rosuvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [52]
Saquinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [53]
Sorafenib Drug Info Pancreatic cancer [ICD-11: 2C10] Approved [54]
Succimer Drug Info Lead poisoning [ICD-11: NE61] Approved [55]
Sulfasalazine Drug Info Rheumatoid arthritis [ICD-11: FA20] Approved [56]
Sulfinpyrazone Drug Info Arthritis [ICD-11: FA5Z] Approved [57]
Technetium (99MTC) mebrofenin Drug Info Imaging of liver and gallbladder [ICD-11: XD47Y1] Approved [4]
Telithromycin Drug Info Community acquired pneumonia [ICD-11: CA40] Approved [16]
Temocaprilate Drug Info High blood pressure [ICD-11: BA00] Approved [4]
Temocaprilate Drug Info High blood pressure [ICD-11: BA00] Approved [3]
Valproic Acid Drug Info Epilepsy [ICD-11: 8A6Z] Approved [3]
Valsartan Drug Info High blood pressure [ICD-11: BA00] Approved [58]
Vasopressin Drug Info Enuresis [ICD-11: 6C00] Approved [59]
Vinblastine Drug Info Testicular cancer [ICD-11: 2C80] Approved [60]
Vincristine Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [4]
Clinical Trial Drug(s) Transported by This DT Belotecan Drug Info Non-small cell lung cancer [ICD-11: 2C25] Phase 3 [29]
Camptothecin Drug Info Non-small cell lung cancer [ICD-11: 2C25] Phase 3 [3]
Glycocholic acid Drug Info Bile acid synthesis defect [ICD-11: 5C52.11] Phase 3 [61]
Phenethyl isothiocyanate Drug Info Cancer [ICD-11: 2A00-2F9Z] Phase 3 [62]
5-methyltetrahydrofolate Drug Info Asthma [ICD-11: CA23] Phase 2/3 [29]
(-)-Epicatechin Drug Info Becker muscular dystrophy [ICD-11: 8C70.0] Phase 2 [63]
BQ-123 Drug Info ST-Elevation myocardial infarction [ICD-11: BA41.0] Phase 2 [29]
Glutathione-S-S-glutathione Drug Info Ovarian cancer [ICD-11: 2C73] Phase 2 [64]
SN-38 Drug Info Colon cancer [ICD-11: 2B90.Z] Phase 2 [65]
Talinolol Drug Info Gastrointestinal motility disorder [ICD-11: DE2Z] Phase 1 [66]
Tauroursodeoxycholate Drug Info Asthma [ICD-11: CA23] Phase 1 [67]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT Aminohippuric acid Drug Info Renal function tests [ICD-11: MG02] Withdrawn [68]
Phenolphthalein Drug Info Constipation [ICD-11: ME05.0] Withdrawn [69]
Rhodamine 123 Drug Info Prostate cancer [ICD-11: 2C82] Discontinued in Phase 1 [70]
Alpha-Zearalenol Drug Info Cardiovascular disease [ICD-11: BE2Z] Preclinical [71]
Chelerythrine Drug Info Staphylococcus aureus infection [ICD-11: 1C41] Preclinical [29]
Scutellarin Drug Info Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical [72]
Sodium taurocholate Drug Info Type 2 diabetes [ICD-11: 5A11] Preclinical [73]
Taxifolin Drug Info Ovarian cancer [ICD-11: 2C73] Preclinical [74]
Sincalide Drug Info Discovery agent [ICD-11: N.A.] Preclinical [19]
Endogenous Substrate(s) Alkaloids; Bilirubin glucuronides; Cysteinyl leukotrienes; E2 17 beta glucuronide; Epipodophyllotosine; Glutahione conjugates; Glutathione dilsulfide; Hepatic canalicular conjugates; Reduced glutathione; Taruochenodeoxycholate sulfate; Taurolithocholate sulfate; Dehydroepiandrosterone sulfate
Endogenous Metabolites (EMs) Handled by This DT 2-(3,4-dihydroxyphenyl)acetic acid EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
3,4-dihydroxyphenylglycol EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
3-hydroxypropanoic acid EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
4-hydroxyhippuric acid EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Caffeic acid EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Caffeine EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Dodecanoic acid EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Resorcinol EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Aminohippuric acid Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 880 microM [68]
Aminohippuric acid Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 2100 microM [76]
Aminohippuric acid Drug Info Spodoptera frugiperda (Sf9) cells-MRP2 Km = 5000 microM [76]
Bilirubin Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 0.7 microM [77]
Bilirubin Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 0.9 microM [77]
Estradiol-17beta-glucuronide Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 7.2 microM [78]
Etoposide Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 617 microM [20]
Irinotecan Drug Info Bile canalicular membrane vesicles-MRP2 Km = 48.9 microM [65]
Irinotecan Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 90.8 microM [32]
Methotrexate Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 480 microM [79]
Olmesartan medoxomil Drug Info LLC-PK1 cells-MRP2 Km = 14.9 microM [41]
SN-38 Drug Info Bile canalicular membrane vesicles-MRP2 Km = 180 microM [65]
Valsartan Drug Info LLC-PK1 cells-MRP2 Km = 30.4 microM [58]
Vinblastine Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 137.3 microM [80]
References
1 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
2 Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86.
3 Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
5 MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
6 Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004 Mar;48(3):809-14.
7 A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
8 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
9 Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
10 Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
11 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
12 Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8.
13 Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23.
14 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
15 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
16 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
17 Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
18 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
19 Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
20 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
21 Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17.
22 Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76.
23 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
24 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
25 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
26 Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010 Aug 16;395(1-2):251-9.
27 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
28 Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007 Nov;46(5):1597-610.
29 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
30 Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
31 Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
32 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
33 Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
34 Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
35 Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006 Oct;62(10):871-5.
36 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
37 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
38 C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
39 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
40 P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
41 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
42 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
43 Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
44 Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15.
45 Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
46 Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
47 Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
48 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9.
49 Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5.
50 Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
51 Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
52 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
53 Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
54 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
55 MRP2 involvement in renal proximal tubular elimination of methylmercury mediated by DMPS or DMSA. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):10-7.
56 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
57 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
58 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
59 Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41.
60 Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
61 Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003 Jun 27;278(26):23529-37.
62 Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol. 2005 Aug 15;70(4):640-7.
63 Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res. 2001 Oct;18(10):1420-5.
64 Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. Eur J Biochem. 1999 Oct 1;265(1):281-9.
65 Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.
66 FDA Drug Development and Drug Interactions
67 Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther. 2007 Feb;320(2):893-9.
68 ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
69 Biliary excretion of phenolphthalein sulfate in rats. Pharmacology. 2003 Aug;68(4):177-82.
70 Characterization of rhodamine-123, calcein and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur J Pharm Sci. 2011 Aug 17;43(5):359-69.
71 ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol Lett. 2009 Oct 28;190(2):215-23.
72 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
73 Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
74 Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp. Int J Pharm. 2009 Aug 13;378(1-2):1-8.
75 Single nucleotide polymorphisms of ABCC2 modulate renal secretion of endogenous organic anions. Biochem Pharmacol. 2017 Sep 15;140:124-138.
76 Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004 Nov;15(11):2828-35.
77 Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90.
78 Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929-37.
79 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
80 Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.